The internationally active patient recruitment specialist Clariness supports the German subsidiary SERVIER Forschung-und-Pharma-Entwicklung of the French pharmaceutical company SERVIER in the digital recruitment of a clinical trial through the ClinLife portal in Germany.
Primary Sjögren’s syndrome is an autoimmune disease that mainly attacks the salivary and lacrimal glands. Worldwide, about 60 out of 100,000 people are affected by this disease.
“So far, there is no targeted treatment that has proven to be effective. Treatment is therefore individualised and depends on the type and extent of symptoms. Current treatment options mainly include the use of symptomatic agents such as tear and saliva substitutes, saliva stimulating substances and pain medication,” says the French pharmaceutical company SERVIER.
A new drug is currently in development that is a biological therapy using an antibody to suppress the inflammatory processes that occur in primary Sjögren’s syndrome.
A Phase II trial is currently underway to further develop the drug. For this purpose, SERVIER Forschung- und Pharma-Entwicklung is cooperating with Clariness, an internationally active specialist for patient recruitment.
“We are delighted to have signed our first contract with Servier Forschung-und-Pharma-Entwicklung for our ClinLife Registry product. We are providing patient recruitment support at various sites in Germany,” says Moritz Kloss, vice-president of ClinLife Registry at Clariness. Patient recruitment with the indication Primary Sjögren’s Syndrome started in the first quarter of 2022.